Evidence map›Paper›PMID 38062925›Full record

Observational studyCancer medicine2023

Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival.

Kyoko Oura, Asahiro Morishita, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Masafumi Ono, Takashi Himoto and 1 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kyoko OuraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.ORCID 0000-0002-9531-7240
Asahiro MorishitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.ORCID 0000-0002-0760-3045
Kei TakumaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Mai NakaharaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Tomoko TadokoroDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.ORCID 0000-0001-9975-386X
Koji FujitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.ORCID 0000-0001-9390-7565
Shima MimuraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Joji TaniDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.ORCID 0000-0001-8801-2505
Masafumi OnoDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Takashi HimotoDepartment of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa, Japan.
Tsutomu MasakiDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Kagawa University · JPKagawa Prefectural College of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimIndications of drug therapies to elderly patients with hepatocellular carcinoma (HCC) should be carefully determined. The current study assessed the safety and efficacy of molecular targeted agents (MTAs) in the elderly patients with HCC, and identified factors associated with prognosis in a real-world clinical setting.

methodsIn a retrospective observational study, clinical data of patients with unresectable HCC treated with sorafenib or lenvatinib as first-line treatment at our hospital between 2011 and 2022, were investigated. Clinical parameters, therapeutic effects, adverse events (AEs), and prognosis were evaluated separately for the non-elderly (<75 years old) and elderly patients (≥75 years old).

resultsOverall, 111 patients were enrolled, including 59 non-elderly and 52 elderly patients. Compared to the non-elderly patients, the elderly patients had significantly lower skeletal muscle mass and a significantly lower percentage of patients in poor general condition with performance status 2 or higher, but there were no differences in parameters related to liver function or nutritional status. There were no significant differences in the incidence of severe AEs and therapeutic effects between the groups. No significant difference in progression-free survival was observed in the elderly and non-elderly patients; however, overall survival (OS) for sorafenib treatment was shorter in the elderly patients than in the non-elderly patients. Elderly patients consumed lower doses of both the drugs, and relative dose intensity (RDI) 4 weeks after treatment (4W-RDI) was associated with OS. Further, OS in the elderly patients was significantly longer in the subgroup with high 4W-RDI as compared to that in the subgroup with low 4W-RDI.

conclusionsMTAs can be safely administered to elderly patients with HCC. Furthermore, 4W-RDI is associated with longer OS. Maintaining RDI in the early phase is crucial in predicting the success of treatment with MTAs, especially in the elderly patients.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsAgedHumansMiddle AgedMolecular Targeted TherapySorafenibTreatment OutcomeAntineoplastic AgentsSorafenibhepatocellular carcinomalenvatinibmolecular targeted agentsorafenibtyrosine kinase inhibitor

Identifiers

PMID38062925
PMCPMC10757153
OpenAlexW4389483091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.